Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Impulsivity is common in Parkinson's disease even in the absence of impulse control disorders. It is likely to be multifactorial, including a dopaminergic 'overdose' and structural changes in the frontostriatal circuits for motor control. In addition, we proposed that changes in serotonergic projections to the forebrain also contribute to response inhibition in Parkinson's disease, based on preclinical animal and human studies. We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves response inhibition, in terms of both behaviour and the efficiency of underlying neural mechanisms. This multimodal magnetic resonance imaging study used a double-blind randomized placebo-controlled crossover design with an integrated Stop-Signal and NoGo paradigm. Twenty-one patients with idiopathic Parkinson's disease (46-76 years old, 11 male, Hoehn and Yahr stage 1.5-3) received 30 mg citalopram or placebo in addition to their usual dopaminergic medication in two separate sessions. Twenty matched healthy control subjects (54-74 years old, 12 male) were tested without medication. The effects of disease and drug on behavioural performance and regional brain activity were analysed using general linear models. In addition, anatomical connectivity was examined using diffusion tensor imaging and tract-based spatial statistics. We confirmed that Parkinson's disease caused impairment in response inhibition, with longer Stop-Signal Reaction Time and more NoGo errors under placebo compared with controls, without affecting Go reaction times. This was associated with less stop-specific activation in the right inferior frontal cortex, but no significant difference in NoGo-related activation. Although there was no beneficial main effect of citalopram, it reduced Stop-Signal Reaction Time and NoGo errors, and enhanced inferior frontal activation, in patients with relatively more severe disease (higher Unified Parkinson's Disease Rating Scale motor score). The behavioural effect correlated with the citalopram-induced enhancement of prefrontal activation and the strength of preserved structural connectivity between the frontal and striatal regions. In conclusion, the behavioural effect of citalopram on response inhibition depends on individual differences in prefrontal cortical activation and frontostriatal connectivity. The correlation between disease severity and the effect of citalopram on response inhibition may be due to the progressive loss of forebrain serotonergic projections. These results contribute to a broader understanding of the critical roles of serotonin in regulating cognitive and behavioural control, as well as new strategies for patient stratification in clinical trials of serotonergic treatments in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
On the ability to inhibit thought and action: a theory of an act of control
Logan, G. D., & Cowan, W. B. (1984) · Psychological Review · doi:10.1037/0033-295x.91.3.295 · Cited by 2,590 · cited 2×
“The behavioural effect correlated with the citalopram-induced enhancement of prefrontal activation and the strength of preserved structural connectivity between the frontal and striatal regions.”
BackgroundMethodRubia, K., Russell, T., Overmeyer, S., Brammer, M. J., Bullmore, E. T., Sharma, T., Simmons, A., Williams, S. C. R., Giampietro, V., Andrew, C. M., et al. (2001) · NeuroImage · doi:10.1006/nimg.2000.0685 · Cited by 999 · cited 2×
“Second, we focused on the right inferior frontal gyrus because this region is consistently associated with motor inhibition in many different versions of NoGo and Stop-Signal tasks (Rubia et al., 2001).”
MethodChamberlain, S. R., Blackwell, A. D., Fineberg, N. A., Robbins, T. W., & Sahakian, B. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.11.006 · Cited by 830
Self-citationCognitive Inflexibility After Prefrontal Serotonin Depletion
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004) · Science · doi:10.1126/science.1094987 · Cited by 632
Self-citationLevy, B. J., & Wagner, A. D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05958.x · Cited by 625
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 5×
“Animal and human studies have often not shown an effect of serotonin on Stop-Signal tasks (as measured by the Stop-Signal reaction time, SSRT) (Clark et al., 2005; Chamberlain et al., 2006, 2007b; Bari et al., 2009; Eagle et al., 2009; Drueke et al., 2010; Nandam et al., 2011).”
BackgroundResultInfluentialSelf-citationEagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548 · cited 3×
“In the ‘Introduction’ section we highlighted the possible psycho- pharmacological differences between action restraint and action cancellation, with evidence for serotonergic regulation of the former, but not latter, type of inhibition (Eagle et al., 2008).”
BackgroundSelf-citationDistinct frontal systems for response inhibition, attentional capture, and error processing
Sharp, D. J., Bonnelle, V., De Boissezon, X., Beckmann, C. F., James, S. G., Patel, M. C., & Mehta, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000175107 · Cited by 535 · cited 1×
“Attentional reorienting to task-relevant stimuli is a feature of both NoGo and Stop-Signal trials (Levy and Wagner, 2011) but also of ‘continue’ trials, which are associated with right inferior frontal gyrus activation in the absence of inhibition (Sharp et al., 2010).”
BackgroundSerotonin and dopamine: unifying affective, activational, and decision functions.
Cools, R., Nakamura, K., & Daw, N. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.121 · Cited by 464
Research works printed but not linked: 58
- Agnoli, 2012, Dorsal-striatal 5-HT2A and 5-HT2C receptors control impulsivity and perseverative responding in the 5-choice serial reaction time task, Psychopharmacology (Berl), 219, 633, 10.1007/s00213-011-2581-0 · DOI
- Albizu, 2011, Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors, Neuropharmacology, 61, 770, 10.1016/j.neuropharm.2011.05.023 · DOI · Paper page
- Anderson, 2002, 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI, Neuroreport, 13, 1547, 10.1097/00001756-200208270-00012 · DOI · Paper page
- Baarendse, 2012, Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats, Psychopharmacology (Berl), 219, 13, 10.1007/s00213-011-2576-x · DOI · Paper page
- Badre, 2007, Left ventrolateral prefrontal cortex and the cognitive control of memory, Neuropsychologia, 45, 2883, 10.1016/j.neuropsychologia.2007.06.015 · DOI · Paper page
- Bari, 2009, Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats, Psychopharmacology (Berl), 205, 273, 10.1007/s00213-009-1537-0 · DOI · Paper page
- Bentivoqlio, 2012, Neuropsychological features of patients with Parkinson's disease and impulse control disorders, Neuro Sci, 34, 1207, 10.1007/s10072-012-1224-5 · DOI
- Borroto-Escuela, 2010, Dopamine D2 and 5-hydroxytryptamine 5-HT(2A) receptors assemble into functionally interacting heteromers, Biochem Biophys Res Commun, 401, 605, 10.1016/j.bbrc.2010.09.110 · DOI
- Burghardt, 2004, The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine, Biol Psychiatry, 55, 1171, 10.1016/j.biopsych.2004.02.029 · DOI · Paper page
- Bymaster, 2002, Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex, Psychopharmacology (Berl), 160, 353, 10.1007/s00213-001-0986-x · DOI · Paper page
- Chamberlain, 2007, Lack of deleterious effects of buspirone on cognition in healthy male volunteers, JPsychopharmacol, 21, 210, 10.1177/0269881107068066 · DOI · Paper page
- Cilia, 2011, Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis, Mov Disord, 26, 225, 10.1002/mds.23480 · DOI · Paper page
- Cools, 2005, Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity, Neuropsychopharmacology, 30, 1362, 10.1038/sj.npp.1300704 · DOI
- Costa, 2013, Methylphenidate effects on neural activity during response inhibition in healthy humans, Cereb Cortex, 23, 117989, 10.1093/cercor/bhs107 · DOI · Paper page
- Crean, 2002, Effect of tryptophan depletion on impulsive behavior in men with or without a family history of alcoholism, Behav Brain Res, 136, 349, 10.1016/S0166-4328(02)00132-8 · DOI
- Crockett, 2009, Reconciling the role of serotonin in behavioral inhibition and aversion: acute tryptophan depletion abolishes punishment-induced inhibition in humans, J Neurosci, 29, 11993, 10.1523/JNEUROSCI.2513-09.2009 · DOI · Paper page
- Cubillo, 2012, Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys, Cereb Cortex, 24, 174, 10.1093/cercor/bhs296 · DOI · Paper page
- Drueke, 2010, Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers, Hum Psychopharmacol, 25, 472, 10.1002/hup.1141 · DOI · Paper page
- Eagle, 2009, Serotonin depletion impairs waiting but not stop-signal reaction time in rats: implications for theories of the role of 5-HT in behavioral inhibition, Neuropsychopharmacology, 34, 1311, 10.1038/npp.2008.202 · DOI
- Fletcher, 2007, Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test, Psychopharmacology (Berl), 195, 223, 10.1007/s00213-007-0891-z · DOI · Paper page
- Goldstein, 2011, Catechols in post-mortem brain of patients with Parkinson disease, Eur J Neurol, 18, 703, 10.1111/j.1468-1331.2010.03246.x · DOI
- Harmer, 2013, ‘It's the way that you look at it’–a cognitive neuropsychological account of SSRI action in depression, Philos Trans R Soc B Biol, 368, 20120407, 10.1098/rstb.2012.0407 · DOI · Paper page
- Harrison, 1999, Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination, Behav Brain Res, 100, 99, 10.1016/S0166-4328(98)00117-X · DOI
- Haugbøl, 2007, Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome, Int J Neuropsychopharmacol, 10, 245, 10.1017/S1461145706006559 · DOI · Paper page
- Homberg, 2007, Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility, Eur J Neurosci, 26, 2066, 10.1111/j.1460-9568.2007.05839.x · DOI · Paper page
- Hughes, 2010, Parkinson's disease and healthy aging: independent and interacting effects on action selection, Hum Brain Mapp, 31, 1886, 10.1002/hbm.20979 · DOI · Paper page
- Humpston, 2013, Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task, J Psychopharmacol, 27, 213, 10.1177/0269881112466182 · DOI
- Khullar, 2011, Wavelet-based fMRI analysis: 3-D denoising, signal separation, and validation metrics, Neuroimage, 54, 2867, 10.1016/j.neuroimage.2010.10.063 · DOI
- Kirby, 2011, Contributions of serotonin in addiction vulnerability, Neuropharmacology, 61, 421, 10.1016/j.neuropharm.2011.03.022 · DOI · Paper page
- LeMarquand, 1999, Behavioral disinhibition induced by tryptophan depletion in nonalcoholic young men with multigenerational family histories of paternal alcoholism, Am J Psych, 156, 1771, 10.1176/ajp.156.11.1771 · DOI · Paper page
- Lewis, 2003, Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry, JNeurosci, 23, 6351, 10.1523/JNEUROSCI.23-15-06351.2003 · DOI · Paper page
- Macoveanu, 2013, Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition, Neuropsychopharmacology, 38, 996, 10.1038/npp.2012.264 · DOI · Paper page
- Mendelsohn, 2009, Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review, Neurosci Biobehav Rev, 33, 926, 10.1016/j.neubiorev.2009.03.006 · DOI · Paper page
- Miyazaki, 2011, Activation of the central serotonergic system in response to delayed but not omitted rewards, Eur J Neurosci, 33, 153, 10.1111/j.1460-9568.2010.07480.x · DOI · Paper page
- Moret, 1996, Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain, Eur J Pharmacol, 295, 189, 10.1016/0014-2999(95)00646-X · DOI
- Nandam, 2011, Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability, Biol Psychiatry, 69, 902, 10.1016/j.biopsych.2010.11.014 · DOI
- Nombela, 2014, Multiple modes of impulsivity in Parkinson's disease, PLoS One, 9, e85747, 10.1371/journal.pone.0085747 · DOI · Paper page
- Obeso, 2011, Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease, Exp Brain Res, 212, 371, 10.1007/s00221-011-2736-6 · DOI · Paper page
- Ortega, 2012, Regulation of central noradrenergic activity by 5-HT(3) receptors located in the locus coeruleus of the rat, Neuropharmacology, 62, 2472, 10.1016/j.neuropharm.2012.02.018 · DOI
- Peelle, 2010, Evaluating an acoustically quiet EPI sequence for use in fMRI studies of speech and auditory processing, Neuroimage, 52, 1410, 10.1016/j.neuroimage.2010.05.015 · DOI
- Politis, 2010, Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study, Neurobiol Dis, 40, 216, 10.1016/j.nbd.2010.05.028 · DOI · Paper page
- Politis, 2012, Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts, Sci Transl Mede, 4, 128ra41
- Rae, 2012, White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function, Neuroimage, 62, 1675, 10.1016/j.neuroimage.2012.06.012 · DOI · Paper page
- Robinson, 2008, Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task, Neuropsychopharmacology, 33, 2398, 10.1038/sj.npp.1301636 · DOI
- Robinson, 2008, Recurrence in major depressive disorder: a neurocognitive perspective, Psychol Med, 38, 315, 10.1017/S0033291707001249 · DOI · Paper page
- Rowe, 2008, Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition, Brain, 131, 2094, 10.1093/brain/awn112 · DOI · Paper page
- Sangkuhl, 2011, PharmGKB summary: citalopram pharmacokinetics pathway, Pharmacogenet Genomics, 21, 769, 10.1097/FPC.0b013e328346063f · DOI · Paper page
- Smith, 2006, Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data, Neuroimage, 31, 1487, 10.1016/j.neuroimage.2006.02.024 · DOI · Paper page
- Swick, 2011, Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks, Neuroimage, 56, 1655, 10.1016/j.neuroimage.2011.02.070 · DOI · Paper page
- Tomlinson, 2010, Systematic review of Levodopa dose equivalency reporting in Parkinson's disease, Mov Disord, 25, 2649, 10.1002/mds.23429 · DOI · Paper page
- Voon, 2011, Impulse control disorders in Parkinson's disease: recent advances, Curr Opin Neurol, 24, 324, 10.1097/WCO.0b013e3283489687 · DOI · Paper page
- Voon, 2011, Impulse control disorders in Parkinson disease: a multicenter case—control study, Ann Neurol, 69, 986, 10.1002/ana.22356 · DOI · Paper page
- Walker, 2009, Differential contributions of dopamine and serotonin to orbitofrontal cortex function in the marmoset, Cereb Cortex, 19, 889, 10.1093/cercor/bhn136 · DOI · Paper page
- Weintraub, 2011, Neurodegeneration across stages of cognitive decline in Parkinson's disease, Arch Neurol, 68, 1562, 10.1001/archneurol.2011.725 · DOI · Paper page
- Weintraub, 2010, Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients, Arch Neurol, 67, 589, 10.1001/archneurol.2010.65 · DOI · Paper page
- Winstanley, 2005, Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders, Neuropsychopharmacology, 30, 669, 10.1038/sj.npp.1300610 · DOI · Paper page
- Zepf, 2008, Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition, Pharmacopsychiatry, 41, 60, 10.1055/s-2007-1004593 · DOI · Paper page
- Zhang, 2012, Selection and inhibition mechanisms for human voluntary action decisions, Neuroimage, 63, 392, 10.1016/j.neuroimage.2012.06.058 · DOI
Cited by
Cam-CAN, Shafto, M. A., Tyler, L. K., Dixon, M., Taylor, J. R., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., et al. (2014) · BMC Neurology · doi:10.1186/s12883-014-0204-1 · Cited by 707
Self-citationFractionating impulsivity: neuropsychiatric implications
Dalley, J. W., & Robbins, T. W. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.8 · Cited by 607
Self-citationA fronto–striato–subthalamic–pallidal network for goal-directed and habitual inhibition
Jahanshahi, M., Obeso, I., Rothwell, J. C., & Obeso, J. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4038 · Cited by 521
Rae, C. L., Hughes, L. E., Anderson, M. C., & Rowe, J. B. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3093-13.2015 · Cited by 274
Self-citationImproving response inhibition systems in frontotemporal dementia with citalopram
Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv133 · Cited by 100
“This is consistent with changes in activation of inferior frontal gyrus after serotonergic modulation in health (Macoveanu et al., 2013) and in Parkinson’s disease (Ye et al., 2014).”
BackgroundResultInfluentialSelf-citationSkandali, N., Rowe, J. B., Voon, V., Deakin, J. B., Cardinal, R. N., Cormack, F., Passamonti, L., Bevan-Jones, W. R., Regenthal, R., Chamberlain, S. R., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0229-z · Cited by 89
Self-citationReorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia
Hughes, L. E., Rittman, T., Robbins, T. W., & Rowe, J. B. (2018) · Brain · doi:10.1093/brain/awy176 · Cited by 81
“Whilst we explicitly examined the modelled interactions between three frontal cortical regions and suggest explanations of beta desynchronization based on cortical network dynamics, we acknowledge that additional regions have been associated with response inhibition (Ye et al., 2014; Rae et al., 2016) but deeper sourc…”
BackgroundMethodSelf-citationDysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Atomoxetine and citalopram alter brain network organization in Parkinson’s disease
Borchert, R. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, S. P., Vatansever, D., Vázquez Rodríguez, P., Ye, Z., Nombela, C., Hughes, L. E., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz013 · Cited by 14
Self-citation
Metadata
- Authors
- Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-27
- Volume
- 137
- Issue
- 4
- Pages
- 1145-1155
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2138881918
- Cited by
- 118
- References
- 30
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.